Oral chemotherapy: Potential benefits and limitations

Clinical and Translational Oncology

Volumn 6, Issue 6, 2004, Pages 335-340

  Batlle, Jaime Feliu ^a   Arranz, Enrique Espinosa ^a   De Castro Carpeño, Javier ^a   Sáez, Enrique Casado ^a   Auñón, Pilar Zamora ^a   Sánchez, Andrés Redondo ^a   Barón, Manuel González ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bioavailability; Compliance; Oral chemotherapy; Preferences; Quality of life

Indexed keywords

EID: 78751632530     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02710062     Document Type: Article

References (50)

1. Greco AF. Evolving role of oral chemotherapy for the treatment of patients with neoplasm. Oncology 1998; Suppl 4:43-50.
2. Gridelli C, Rossi A, Guerriero C, et al. Oral cytotoxic drugs. Suppl Tumori 2002;Suppl 1:19-23.
3. De Bruijn EA, Slee PH, Van Oosterom AT, et al. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm Weekbl Sci 1988;10:200-6.
4. Philips TA, Howell A, Grieve R, et al. Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci 1980;69:1428-31.
5. Wurthwein G, Krumpelmann S, Tillmann B, et al. Population pharmacokinetic approach to compare oral and intravenous administration of etoposide. Anticancer Drugs 1999;10:807-14.
6. Antilla MI, Sotaniemi EA, Kairaluoma MI, et al. Pharmacokinetics of Tegafur after i.v and oral administration. Cancer Chemother Pharmacol 1983;10:150-3.
7. Poplack DG, Balis FM, Zimm S. The pharmacology of orally-administered chemotherapy: A reappraisal. Cancer 1986;58:473-80.
8. Miller AA, Herndon JE, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small cell lung cancer: A randomised phase III study of the cancer and leukaemia Group B. J Clin Oncol 1995;13:1871-9.
9. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of Uracil/Tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16.
10. Schilsky RL, Levin J, West WH, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002;20:1519-26.
11. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27.
12. Von Pawel J, Gatzeimer U, Pujol JL, et al. Phase II comparator of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-9.
13. Middleton MR, Grobb JJ, Aaronson N, et al. Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
14. Jassem J, Ramlau R, Karnicka-Mlodkowska H, et al. A multicenter randomised phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001;10:1375-81.
15. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study. J Clin Oncol 2001;19:2282-92.
16. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002;87:933-7.
17. Liu G, Franssen E, Fitch M, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.
18. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetic of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58.
19. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomised phase III study comparing teozolomide with dacarbazine. Cancer Invest 2003; 21:821-9.
20. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35: 1505-9.
21. Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Dagleish AG, Knight MJ. A phase II study of continuous-infusion 5fluorouracil with cisplatin and epirrubicin in inoperable pancreatic cancer. Br J Cancer 1996;73:1260-4.
22. Cunningham D, Coleman R. New options for outpatient chemotherapy-the role of oral fluoropyrimidines. Cancer Treat Rev 2001;27:211-20.
23. Mayer RJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol 2001;19:4093-6.
24. Gerrits CJ, de Jonge MJ, Schellens JH, et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997;76: 952-62.
25. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentration inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9.
26. Friedlander ML, Tattersall MHN. Counting costs of cancer therapy. Eur J Cancer 1982;18:1237-41.
27. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67.
28. Maroun J, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003;21:1039-51.
29. Chu E, Díaz-Rubio E, Marshall JE, et al. Economic analysis of potential medical cost saving of XELOX (capecitabine and oxaliplatin combination) in metastatic colorectal cancer (MCRC) [abstract 1080]. Proc Am Soc Clin Oncol 2003;22:269.
30. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61.
31. Hudes G. Boosting bioavailability of topotecan: what do we gain? J Clin Oncol 2002;13:2918-9.
32. Schellens JHM, Malingré MM, Kruijtzer CMF, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12:103-10.
33. Sparreboom A, de Jonge MJA, Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer 2002;38:18-22.
34. Hellreigel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996;60:601-7.
35. Handle KR, Krozely MG, Greco FA, et al. Bioavailability of low dose oral etoposide. J Clin Oncol 1993;11:374-7.
36. Hines JD, Zakem MH, Adelstein DJ, et al. Bioavailability of high-dose oral Leucovorin. NCI Monogr 1987;5:57-60.
37. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow J F. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7:2016-21.
38. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41.
39. Kruiijtzer CMF, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glicoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-50.
40. Hoffmeyer S, Burk O, von Ritcher O, et al. Functional polymorphisms of the human multidrugs-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.
41. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
42. Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB 1992;6:745-8.
43. Kobayashi K, Ratain MJ, Fleming GF, et al. A phase I study of CYP3A4 modulation of oral etoposide with ketoconazole in patients with advanced cancer [abstract 1489]. Proc Am Soc Clin Oncol 1996;15:471.
44. Smith D, Margison J, Lucas S. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987;19:138-42.
45. Richardson JL, Marks G, Levine AM. Influence of symptoms of disease and side effects on treatment compliance with cancer therapy. J Clin Oncol 1988;6:1746-52.
46. Blackwel B. Drug therapy: patient compliance. N Engl J Med 1973;289:249-52.
47. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: favorable safety profile compared with intravenous 5fluorouracil / leucovorin. Ann Oncol 2002;13:566-75.
48. González-Barón M, Feliu J, de la Gándara I, et al. Efficacy of oral tegafur modulated with leucovorin modulation by uracil and leucovorin in advanced colorectal cancer: a phase II study. Eur J Cancer 1995;31A:2215-9.
49. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs 2003;7:158-62.
50. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukaemia. N Engl J Med 2003;349:1423-32.